Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

GLP-1 has not only beneficial effects on glucose metabolism but also direct positive effects on cardiac function and metabolism in both experimental models and in patients with type 2 diabetes mellitus. Clinical data on the effects of GLP-1 agonists on cardiac function and glucose control in patients undergoing cardiac surgery are not known. Based on the results of experimental studies there is a potential for exenatide to positively influence both cardiac function and glucose metabolism in cardiac surgery patients with and without type 2 diabetes mellitus. The primary endpoint of this study is to examine whether pre- and peri-operative administration of exenatide affects perioperative hemodynamics, echocardiographic parameters, necessity of antiarrhythmic and inotropic treatment and glucose control in patients with coronary atherosclerosis and decreased left ventricular function undergoing elective coronary artery bypass grafting operation (CABG). In addition, safety and tolerability of peri-operative administration of exenatide in these patients will be examined as a secondary study objective.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Charles University, Czech Republic
• Collaborator: Eli Lilly and Company
• Treatments: Exenatide; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

• elective coronary artery bypass grafting operation (CABG)

• decreased left ventricular (LV) systolic function (EF LV ≤ 50%)

• Age 18 to 85

• Signed informed consent

• Females with childbearing potential have to use appropriate contraceptive measures during the whole study period and 6 months after terminating exenatide infusion (hormonal contraception or double-barrier contraception for both partners)

Exclusion Criteria:

• allergy to exenatide

• allergy to insulin

• mental incapacity or language barrier

• use of incretin-based therapies <3 months before inclusion in the study

• diabetic ketoacidosis

• established autonomic neuropathy

• history of acute pancreatitis or severe disease of digestive tract

• renal failure (preoperative creatinine ≥ 180 umol/l)

• liver failure (coagulation times more than 1.5 times higher without use of anticoagulants)

• cardiac surgical procedure on valve, thoracic aorta or MAZE procedure

• pregnancy and lactation